Long-Term Study of MP-214 in Patients With Schizophrenia

Long-Term Extension Study of MP-214 in Patients With Schizophrenia

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.

Inclusion Criteria:

• Written informed consent obtained from the patient before the completion of Study A002-A4
• Patients who have completed the A002-A4 study

Exclusion Criteria:

• Patients who are experiencing ongoing, uncontrolled, clinically significant adverse events (AEs), as judged by the investigator (or subinvestigator)

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.